bioAffinity Technologies vs OneMedNet
BIAF and ONMD side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIAF and ONMD compare
OneMedNet is the larger company, worth 123 times as much as bioAffinity Technologies ($317M against $2.6M).
OneMedNet grew revenue faster over the last twelve months (217% versus −18.5% for bioAffinity Technologies).
bioAffinity Technologies keeps more of each dollar of sales as profit, with a net margin of −279% compared with −584% at OneMedNet.
bioAffinity Technologies scores higher on the StockData Score (5 against 3 for OneMedNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIAF | ONMD |
|---|---|---|
| Size and price | ||
| Market cap | $2.6M | $317M |
| Share price | $2.20 | $5.34 |
| Change, 1 year | −93.2% | −64.6% |
| Change, 5 years | – | −94.7% |
| Beta (5Y) | −1.10 | −0.24 |
| Employees | 57 | 23 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 217× |
| P/B | 0.7× | – |
| FCF yield | −508% | −2.2% (better) |
| Fair value | $11.85 | – |
| Margin of safety | 81.4% | – |
| Growth | ||
| Revenue growth (TTM) | −18.5% | 217% (better) |
| Profitability | ||
| Gross margin | – | −68.8% |
| Operating margin | −246% (better) | −696% |
| Net margin | −279% (better) | −584% |
| FCF margin | −236% (better) | −473% |
| Return on equity | −240% | – |
| Return on invested capital | −694% | – |
| Financial health | ||
| Debt / equity | 0.05 | – |
| Interest coverage | −270.9× (better) | −307.0× |
| Current ratio | 1.51 (better) | 0.28 |
| Altman Z-score | −19.56 (better) | −99.41 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.1% | 10.2% |
| Held by insiders | – | 6.9% |
| Insider net buying, 12 months | – | $4.1M |
Go deeper
- BIAF stock overview
- BIAF income statement
- BIAF valuation and score
- ONMD stock overview
- ONMD income statement
- ONMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.